Quality Adjust Life Years in Healthcare Disguise Bigotry
 
Newsmax | Sally Pipes
April 29, 2022

What’s the value of a human life? It’s a most provocative question.

In socialized healthcare systems globally, that question is at the center of every decision public officials make: how much money to spend on care, whether to approve an innovative new drug or medical device for use, who gets timely access to treatment, and who has to wait, and so forth.


Read more. . .

New Brief: Broken System Imposes Higher Out-Of-Pocket Costs on Patients, Puts Interests of Government and Insurers First
 
Coverage Denied | Dr. Wayne Winegarden
April 28, 2022

America’s broken third-party healthcare payment system prioritizes government and insurance companies as the largest payers, leaving patients with higher out-of-pocket costs, greater exposure to healthcare financial risk, and reduced access to care – finds the latest paper in the Coverage Denied series released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute.


Read more. . .

Biden must not kill off short-term health plans
 
Washington Examiner | Sally Pipes
May 2, 2022

Democratic lawmakers are looking to limit patient choice in the health insurance market.

Forty of them just sent a letter to the Biden administration urging regulators to undo a Trump-era rule that expanded access to short-term health plans. President Joe Biden is sympathetic to their pleas. He called short-term plans “junk” during his 2020 campaign. But his administration has yet to roll back Donald Trump’s rule.


Read more. . .

The U.S. Should Not Be Funding The WHO Follies

Issues & Insights | Henry Miller
May 4, 2022

The two-years-plus of the COVID-19 pandemic should be a wakeup call that there is something very wrong – irreparable, even – at the chronically inept World Health Organization (WHO). Two recent transgressions show that the bureaucrats there are not getting any smarter.

The first is almost inconceivable. Medicago, a Canadian company, developed a COVID-19 vaccine synthesized in the Nicotiniana plant, a relative of tobacco. In clinical testing, it showed efficacy against all variants studied prior to the emergence of Omicron of 71%, and for the Delta variant specifically of 75%.